Sarona Ventures

Sarona Ventures is a Tel Aviv-based investment firm backing Israeli healthtech founders, writing checks of $250K to $1M at seed and Series A. The firm leans on its European network to facilitate commercial partnerships for portfolio companies, which is a meaningful differentiator in a market where most Israeli investors orient around the United States. Founders building healthtech with European commercialization potential will find Sarona’s positioning more useful than a generic Israeli VC’s.

The thesis covers digital health and AI and machine learning in healthcare. Sarona is interested in companies whose products address clinical or operational problems in healthcare and whose founders are willing to engage seriously with European partners as part of their go-to-market strategy. The firm tends to back B2B software and AI-driven companies rather than consumer wellness plays, and it favors founders with technical or clinical depth. Pre-revenue companies are welcome where the team and technology hold up to scrutiny.

Check sizes of $250K to $1M place Sarona as a participating co-investor in seed and Series A rounds, often alongside larger Israeli and international VCs. The geographic focus is Israel, with active commercial engagement in Europe through the firm’s network of clinical, regulatory, and corporate partners. Founders should expect questions about how they plan to navigate fragmented European reimbursement environments and how they will leverage Israeli technical strengths into European commercial traction. The firm is most useful when European partnerships are part of the company’s strategy rather than an afterthought.

The team includes investors with backgrounds spanning Israeli technology venture, European corporate development, and healthcare operating roles. That bench gives portfolio companies access to advisors and partners who can open commercial doors in European health systems and life-sciences organizations, an asset that few Israeli VCs match in depth.

Sarona Ventures’ working style is hands-on within the constraints of a small fund. The firm typically takes observer roles rather than full board seats and focuses its engagement on commercial strategy, particularly around European partnerships and follow-on fundraising. Sarona co-invests with Israeli VCs, European healthcare-focused funds, and family offices, and supports portfolio companies through subsequent rounds and strategic partnerships. Founders building Israeli healthtech or healthcare AI companies with credible European commercial ambitions, and who want an investor whose network goes meaningfully beyond Israel and the United States, will find Sarona a relevant addition to a round. Founders focused exclusively on the US market will find less differentiation in the relationship and should weigh whether the European angle adds enough to justify the seat.